Bridgeway Capital Management’s Xilio Therapeutics XLO Stock Holding History

Bridgeway Capital Management’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$168K	Buy	+17,544	New	+$147K	﹤0.01%	1094
2026 Q1	–	Sell	-4,006	Closed	-$35.9K	–	1319
2025 Q4	$35.9K	Hold	4,006	–	–	﹤0.01%	1193
2025 Q3	$47.3K	Hold	4,006	–	–	﹤0.01%	1171
2025 Q2	$38.1K	Sell	4,006 -1,071	-21%	-$11.3K	﹤0.01%	1146
2025 Q1	$51.5K	Hold	5,077	–	–	﹤0.01%	1119
2024 Q4	$67.9K	Hold	5,077	–	–	﹤0.01%	1142
2024 Q3	$56K	Hold	5,077	–	–	﹤0.01%	1205
2024 Q2	$67.3K	Hold	5,077	–	–	﹤0.01%	1196
2024 Q1	$76.8K	Sell	5,077 -6,029	-54%	-$58.2K	﹤0.01%	1237
2023 Q4	$85.5K	Buy	11,106 +3,214	+41%	+$63.6K	﹤0.01%	1261
2023 Q3	$233K	Hold	7,892	–	–	0.01%	1068
2023 Q2	$289K	Hold	7,892	–	–	0.01%	1055
2023 Q1	$351K	Hold	7,892	–	–	0.01%	966
2022 Q4	$297K	Buy	7,892 +2,458	+45%	+$82.9K	0.01%	992
2022 Q3	$221K	Buy	+5,434	New	+$211K	0.01%	1122

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bridgeway Capital Management's XLO Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 17,544 shares worth $168K. The stake represents ﹤0.01% of the portfolio and ranks #1094 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in XLO as recently as Q4 2025.

Bridgeway Capital Management first reported a position in XLO in Q3 2022 and has held it in 15 quarters since. The position peaked at $351K in Q1 2023. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

Bridgeway Capital Management held 17,544 shares of Xilio Therapeutics worth $168K as of Q2 2026.
Xilio Therapeutics was a new Bridgeway Capital Management position in Q2 2026.
Xilio Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1094 holding.
Bridgeway Capital Management first reported a position in Xilio Therapeutics in Q3 2022 and has held it in 15 quarters since.
Bridgeway Capital Management's Xilio Therapeutics position peaked at $351K in Q1 2023.
26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.